Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | LTA4H | P09960 | 7/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3044322 | 0.85 | FAAH (0.69) | FAAHLMNAHRH3 | |
| SCHEMBL3031872 | 0.84 | LTA4H (0.77) | FAAHLMNALTA4HHRH3 | |
| SCHEMBL3031867 | 0.84 | LTA4H (0.77) | FAAHLMNALTA4HHRH3 | |
| SCHEMBL3040673 | 0.84 | LMNA (0.72) | FAAHLMNALTA4HHRH3 | |
| SCHEMBL3031047 | 0.82 | LMNA (0.77) | FAAHLMNALTA4HHRH3 | |
| SCHEMBL6287602 | 0.82 | LTA4H (0.69) | LTA4HHDAC8LNPEP | |
| SCHEMBL7369855 | 0.81 | FAAH (0.62) | FAAHHRH3 | |
| SCHEMBL7369861 | 0.81 | FAAH (0.62) | FAAHHRH3 | |
| SCHEMBL7368538 | 0.81 | SLC6A5 (0.61) | LMNAHRH3 | |
| SCHEMBL7364841 | 0.81 | SLC6A5 (0.61) | LMNAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1976828-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Schering Aktiengesellschaft (DE) | 2008-10-08 | — | — | EP | claimed |
| WO-2007079078-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-12 | — | — | WO | claimed |
| US-20230250104-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| US-11267819-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | Celltaxsis, LLC (US) | 2022-03-08 | — | — | US | disclosed |
| US-20200308181-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2020-10-01 | — | — | US | disclosed |
| EP-3205644-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Celtaxsys Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-1976828-B1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS INC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20160272649-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS INC (US) | 2016-09-22 | — | — | US | disclosed |
| US-9315509-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150080382-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | DOMAIN PARTNERS VIII, L.P. | 2015-03-19 | — | — | US | disclosed |
| US-8569303-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130123243-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS, INC. | 2013-05-16 | — | — | US | disclosed |
| US-20100210630-A1 | Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase | ESTRELLITA PHARMACEUTICALS, LLC | 2010-08-19 | — | — | US | disclosed |
| US-7737145-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | ESTRELLITA PHARMACEUTICALS, LLC (US) | 2010-06-15 | — | — | US | disclosed |
| US-20070155726-A1 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123243-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTB4R, LTC4S | FAAH 102/4885LMNA 1679/4885LTA4H 1/4885 |
| US-20150080382-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTB4R, LTC4S | FAAH 102/4885LMNA 1679/4885LTA4H 1/4885 |
| US-20070155726-A1 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | FAAH 102/4885LMNA 1679/4885LTA4H 1/4885 |
| US-11267819-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | FAAH 102/4885LMNA 1679/4885LTA4H 1/4885 |
| US-20230250104-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTB4R, LTC4S | FAAH 102/4885LMNA 1679/4885LTA4H 1/4885 |
| US-20200308181-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTB4R, LTC4S | FAAH 102/4885LMNA 1679/4885LTA4H 1/4885 |
| US-20100210630-A1 | Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | FAAH 102/4885LMNA 1679/4885LTA4H 1/4885 |
| US-20160272649-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTB4R, LTC4S | FAAH 102/4885LMNA 1679/4885LTA4H 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.